Pa. Supreme Court fixes ridiculously overbroad holding of puffery

Commonwealth v. Golden Gate National Senior Care LLC, —
A.3d —-, 2018 WL 4570102, No. 16 MAP 2017 (Pa. Sept. 25, 2018)
The Pennsylvania Supreme Court reinstated a bunch of claims
against a bunch of nursing homes under the state Unfair Trade Protection and
Consumer Protection Law, though not unjust enrichment claims. In essence, the
nursing homes allegedly made materially misleading statements about the nature
and quality of the care provided to their nursing home residents. They
allegedly knowingly failed to provide the level of care they advertised, as
they purposefully understaffed the facilities so as to maximize their profits. Chain-wide
misrepresentations included brochures, videos, websites, and video
advertisements, with claims such as:
“Snacks and beverages of various
types and consistencies are available at any time from your nurse or nursing
assistant.”
“We have licensed nurses and
nursing assistants available to provide nursing care and help with activities
of daily living …. Whatever your needs are, we have the clinical staff to
meet those needs.”
“Clean linens are provided for you
on a regular basis, so you do not need to bring your own.”
“A restorative plan of care is
developed to reflect the resident’s goals and is designed to improve wellness
and function. The goal is to maintain optimal physical, mental and
psychological functioning.”
“A container of fresh ice water is
put right next to your bed every day, and your nursing assistant will be glad
to refill or refresh it for you.’ ”
“We work with an interdisciplinary
team to assess issues and nursing care that can enhance the resident’s
psychological adaptation to a decrease of function, increase levels of
performance in daily living activities, and prevent complications associated
with inactivity.”
In truth, residents allegedly routinely have to wait hours
for food, assistance with toileting, changing of soiled bed linens, and other
elements of basic care, and sometimes must forego them entirely.
On the individual facility level, the AG alleged misrepresentations
in the resident assessment and care plans created for each resident: services
promised in the care plans were not provided because of intentional
understaffing. Also, the facilities allegedly generated billing statements
which indicated that certain care was provided when it was not, which were then
paid by public funds when residents received Medicaid or Medicare. The facilities
allegedly further deceived the Pennsylvania Department of Health by temporarily
increasing the number of staff on hand during inspections and by willfully
creating inaccurate and/or falsified resident care records for review.
The Commonwealth Court found the marketing and advertising
materials to be mere puffery: too broad or vague, or merely expressing an
intent. Then the court held that resident assessments, care plans and bills
weren’t covered by the UTPCPL because they weren’t advertising but rather
isolated statements to potential customers, or in the case of resident care
plans were created after a customer was admitted to a facility. The court also
found that the allegations about care deviating from promises were too
conclusory and unspecific. The AG didn’t identify any  “particular care plan … from which the
Facility deviated, or … identify[ ] any specific bill for services that were
not provided.”  Further, the AG didn’t allege
“how a consumer could be misled by a billing statement to believe that he
received services or assistance that he had not in fact received, or how an
un-itemized per diem charge could convey to a consumer that a particular
service had been provided in the first place.”
Here, the state supreme court identified two types of
puffery: (1) “hyperbolic boasting or bluster that no reasonable consumers would
believe to be true” and (2) “claims of superiority over a competitor’s product,”
though the examples are “statements that a laboratory imaging device provided ‘unprecedented
clarity,’ or the advertisement of a product as ‘the complete sports drink,’” so
I’m pretty sure “claims of superiority” is implicitly modified by “vague or
general,” especially since the court continues by saying that a key
characteristic of puffery is that “consumers understand that the statements are
not to be takenliterally. … It is these characteristics – the patently
hyperbolic or excessively vague character that dissuades any reasonable
consumer from placing reliance thereon as fact – that render puffery
non-actionable under the UTPCPL.”
Puffery is usually a question of fact. It was so here:
We hesitate to conclude that
consumers seeking a nursing home would necessarily find statements promising to
provide food, water, and clean linens to be hyperbolic in any respect, or to be
vague statements of optimism or intent. To the contrary, for residents of
nursing homes, many of whom are physically compromised and require assistance
with day-to-day living activities, regular access to these items is essential,
and there is no reason to think that a consumer would not take these statements
seriously.
Plus, the lower court didn’t consider the overall
context.  For example, it held that, “We
believe that respecting your individuality and dignity is of utmost
importance[,]” qualified as puffery “based on the preface alone” – that is,
based on the use of the phrase “we believe,” which was impermissible slicing
and dicing (something that’s also basic First Amendment defamation doctrine). Nor
was “[a] container of fresh ice water is put right next to your bed every day,
and your nursing assistant will be glad to refill or refresh it for you” mere
optimism or vague, given the obvious message that “a resident will have ready
access to water every day,” something that would be highly relevant to an
immobile resident.
The lower court also erred in holding that statements in
patient assessments, care plans and billing statements weren’t actionable
because they weren’t ads, applying the definition of advertising elaborated by
judges under the Lanham Act. Though some provisions of the UTPCPL specifically
mention advertising, the court pointed to two relevant UTPCPL provisions
covering conduct other than advertising. Subsection (v) prohibits conduct
“[r]epresenting that goods or services have sponsorship, approval, characteristics,
ingredients, uses, benefits or quantities that they do not have or that a
person has a sponsorship, approval, status, affiliation or connection that he
does not have,” and subsection (xxi) prohibits “[e]ngaging in any other
fraudulent or deceptive conduct which creates a likelihood of confusion or of
misunderstanding.”  The court declined to
rewrite the statute to impose the “advertising” limitation on all the provisions.
It further pointed out that other subsections prohibit “failing to comply with
the terms” of a written guarantee or warranty and “making solicitations for
sales of goods or services” without first providing certain information, making
clear that the statute overall wasn’t intended to be limited to “advertising”
under the Lanham Act.
Likewise, the lower court erred in finding the complaint
insufficiently detailed. The AG pled factual allegations based on interviews
with former employees and residents’ family members, as well as on information
from the Centers for Medicare and Medicaid services; the complaint included
representative examples of the alleged failures.  “Pennsylvania is a fact-pleading
jurisdiction; as such, a complaint must provide notice of the nature of the
plaintiff’s claims and also summarize the facts upon which the claims are
based.” But there’s no requirement to plead the evidence upon which the pleader
will rely to later prove the claims. The defendants were informed of the claims
against them, even without identifying particular patients, care plans,
assessments, or bills.
In addition, the lower court erred in holding that the state
couldn’t seek return of monies spent because it wasn’t a “person” under the
statute. The relevant statutory phrase is “person in
interest,” that is, “those whose interests were
affected by the enjoined conduct, i.e., those who lost money or property
because of the enjoinable conduct that was found to violate the UTPCPL.” This included the state when it was the one that lost money, especially given the rule of construction that this consumer protection statute
is to be interpreted liberally.  

from Blogger https://ift.tt/2zwY7Ea

Posted in Uncategorized | Tagged | Leave a comment

modifying a false advertising injunction is justified when likelihood that claim is false has changed

De Simone v. VSL Pharmaceuticals, Inc., No. TDC-15-1356, 2018
WL 4567111 (D. Md. Sept. 24, 2018)
De Simone sought modification of a preliminary
injunction governing statements it could make about a probiotic product, VSL#3

and its relationship to De Simone’s now-competing product, Visbiome.  (I was a bit critical at the time.) They
sought to be able to advertise that ExeGi Pharma was the exclusive provider of
the “De Simone Formulation,” the term they have coined for the combination of
probiotic strains developed by De Simone and first commercialized in the United
States as VSL#3; to cite clinical studies with the term “VSL#3” in the title as
part of their promotional materials; and to engage in other speech critical of
VSL#3.
As relevant here, the prior order required ExeGi to refrain
from “stating or suggesting that the license agreement” between De Simone and
VSL had “expired,” or asserting that “VSL#3 will no longer be on the market.” At
the time, both products, though differently branded, used the same formulation.
Thus, Visbiome’s exclusivity statements were false advertising. The court also
enjoined (apparently 100% truthful) Visbiome statements that studies with
“VSL#3” in the title constituted studies relating to the “De Simone
Formulation.”
The De Simone parties returned to court, arguing that the
VSL product was no longer made under De Simone’s formulation, resulting in a
clinically different composition; VSL agreed that production was now elsewhere
but argued that the changes weren’t clinically significant, and that any
changes were the result of De Simone’s breach of his fiduciary duty so they
shouldn’t be allowed to be communicated to the public.  [You can tell my feelings about that last
part.]
A court has the power “to modify an injunction in adaptation
to changed conditions.”
The court didn’t let De Simone speak truthfully by citing
studies that use the term VSL#3 in the title (while studying the De Simone
formulation). The court previously found the extensive use of the citations to
be confusing and concluded that “[e]ven if ExeGi has a reason to refer to those
studies because Visbiome is, as a scientific matter, the same formulation that was
subjected to those trials, that scientific equivalence cannot be used as an
opportunity or excuse to erode VSL’s trademark.”  Again, “eroding” a trademark isn’t a thing,
but the court determined that the change in the VSL product’s formulation
didn’t constitute a relevant change for trademark purposes.  [Which is an interesting variant on the fact
that trademark doesn’t actually protect the public from changes in quality
initiated by the trademark owner.]  So
now, the De Simone defendants are infringing if they truthfully refer to the
studies, while VSL might be falsely advertising (if the formulation is indeed
materially different) if they refer to the studies. 
However, conditions did change as to representations of
exclusivity. At the time of the old order, while the license agreement between
De Simone and VSL had recently expired, VSL continued to have inventory of
product produced under that agreement, so De Simone’s statements at that time
that they were the “exclusive” provider of the De Simone formulation
constituted false advertising. That’s no longer true, and promotional materials
including those touting VSL#3 as dairy-free, now made clear that VSL#3 and
Visbiome were no longer exactly the same, removing the factual predicate of the
injunction about exclusivity statements. At a minimum, the likelihood of
success of a false advertising claim against the exclusivity statements had
changed: though VSL had offered explanations for the composition discrepancies,
and criticized De Simone’s published studies as biased, they hadn’t submitted a
comparable published study indicating that the current versions of VSL#3 and
Visbiome were identical or even functionally equivalent. Plus, the balance of
equities had shifted because VSL#3 has been marketed as “the same quality
product, containing the same genus and species of bacteria, in the same
proportions that you have come to expect,” while ExeGi couldn’t dispute that.
Thus, the injunction would no longer bar assertions that the
licensing agreement between De Simone and VSL has expired and that ExeGi is the
exclusive provider of the De Simone formulation, but the court refused to
declare broadly that ExeGi is free to “engage in commercial speech critical of
its competitor’s products.” This was warranted particularly because the De
Simone parties had a history of stretching the court’s orders to the breaking
point, and also because a trial was upcoming to resolve the factual disputes.
Until trial, the exclusivity statement would have to read: “We believe that
ExeGi is the exclusive provider of the De Simone Formulation because it is our
position that the current version of VSL#3 uses a different formulation.
Whether VSL#3 presently uses the De Simone Formulation is the subject of
pending litigation in federal court.”

from Blogger https://ift.tt/2Q4R22M

Posted in Uncategorized | Tagged , | Leave a comment

falsity from former customer satisfies Lexmark standard; not so for once-potential customer

Frompovicz v. Niagara Bottling, LLC, No.. 18-54, 2018 WL
4465879  (E.D. Pa. Sept. 18, 2018)
Prior
ruling covered here
. Plaintiff (on behalf of a putative class) is a
water extractor. Defendant Land is a directly competing extractor and the
bottler/distributor defendants who use his water are Niagara, Ice River, and
Crossroads. Land allegedly extracts well water, which “does not satisfy the
FDA’s definition of ‘spring water’ ” and which is permitted by the Pennsylvania
Department of Environmental Protection (DEP) as a “well water” site, and not a
“spring water” site. Land’s water allegedly “has been extracted, handled, or
treated with equipment or techniques that are inconsistent with a ‘spring
water’ classification criteria” and “has tested as containing more particulates
or trace elements than are otherwise permissible or recommended under industry
standards for ‘spring water.’ ”  Niagara
and Ice River sourced their spring water from plaintiff before switching to
Land, and Crossroads also considered plaintiff’s water before choosing
Land.  Plaintiff also allegedly bottled
and sold his own water directly.
Plaintiff satisfied Lexmark’s
zone of interests test by alleging that his spring water sales were depressed
as a result of the misleading labels. Also, Niagara allegedly “falsely told
industry participants that Plaintiff should not be dealt with, and has
misrepresented to the public that Plaintiff’s spring water…is contaminated.”
Land also allegedly disparaged the plaintiff, which affected the necessary
commercial interest in reputation or sales.
Proximate cause: simple as to Land, because they’re direct
competitors. Lexmark also allows
suits against indirect competitors, though the circumstances have to be
relatively unique. Here, the alleged disparagement by Niagara qualified: “when
a party claims reputational injury from disparagement, competition is not
required for proximate cause.”  Plaintiff
also alleged that if the bottler defendants wanted to meet the demand for
spring water without Land’s “phony” spring water, they’d have to use his and
other putative class members’ true spring water. The bottler defendants argued
that this allegation was merely speculative because there was no reason to
think they would have bought from Land instead. But as to defendants who
formerly bought from Land, the theory that they would have continued to buy
from him in the absence of the mislabeling was a plausible theory of proximate
cause.  Crossroads never bought from
Land, though, and it wasn’t enough to allege that they were in negotiations at
one point.
The Pennsylvania unfair competition claims were preempted by
the FDCA, which has promulgated
 a standard of identity
for bottled water, including a definition of “spring water.” The allegation
that it was misleading to market Land’s water as “spring water” when the
Pennsylvania DEP permit identified the source as a “well water” site was
precisely the kind of claim prohibited by the FDCA.  The FDCA also impliedly preempts a state law
claim based on conduct that is wrongful only because it conflicts with the FDCA
or FDA regulations.  Land’s allegations
were, in effect, a prohibited attempt to enforce alleged violations of the FDCA
and FDA regulations.

from Blogger https://ift.tt/2xVgOPV

Posted in Uncategorized | Tagged | Leave a comment

failure to detail harm dooms medical food complaint despite plausible falsity

Alfasigma USA, Inc. v. Nivagen Pharmaceuticals, Inc., 2018
WL 4409350, No. 2:17-cv-01974-MCE-GGH (E.D. Cal. Sept. 17, 2018)
Somewhat surprisingly, failure to tell a detailed harm story
torpedoes this complaint; given the specific allegations of falsity, I wonder if it
will be successfully amended (as the court allowed).
Alfasigma makes “medical foods,” which can be prescribed but
do not require prescriptions. They are not eligible for reimbursement by
Medicaid, Medicare, or many private insurers. Breckenridge makes a purportedly generic
version of Alfasigma’s Foltx called Folbic. Pharma databases allegedly link
generic foods to name brand equivalents on the honor system, without
verification by any independent entity. Thus, relying on a company’s
representation that its product contains the same active ingredients in the
same amounts as a listed brand or equivalent generic product, industry
databases will represent to the pharmaceutical industry that the generic
product is pharmaceutically equivalent to the listed products.
Nivagen began marketing a generic—Niva-Fol— that it
represented was equivalent to Alfasigma’s branded product, Foltx, and
Breckenridge’s generic, Folbic. However, Nivagen allegedly characterized its
product as a prescription drug that requires an “Rx” on the label, thereby
entitling users to reimbursement. Nivagen allegedly caused Niva-Fol to be shown
as having a National Drug Code (“NDC”) or National Health Related Items Code
(“NHRIC”) number, which identifiers are provided for approved drugs and medical
devices only. Those identifiers also appear to qualify Niva-Fol for federal
reimbursement. Finally, Nivagen allegedl falsely designated its product as
“Made in the USA.” This allegedly gave Nivagen a competitive advantage over
non-reimbursable products offered by Alfasigma, allowing it to capture market
share.
Even applying Rule 9, the complaint sufficiently pled false
advertising (except for the “Made in the USA” part, which didn’t even pass Rule
8 scrutiny).
Nivagen argued that the complaint failed to allege the factual
basis for Alfasigma’s belief that Niva-Fol lacks the same active ingredients as
Alfasigma’s products, or why it is not substitutable, or why any of the
challenged representations would be misleading, or how Nivagen got the
NDC/NHRIC designations if that wasn’t ok. 
None of that was a problem; the allegations Alfasigma did make sufficed.
“Though Plaintiff does not allege the exact statements made to the FDA, or even
who made them, this case does not lend itself to Plaintiffs having those kind
of details at this point. If the allegations are to be substantiated, that
information is known only to Defendant at this time, and is not required to be
pleaded up front.”  Arguments about
whether Niva-Fol really was entitled to an Rx designation were not suitable for
judgment on the pleadings. The only exception was “Made in the USA,” where
Alfasigma didn’t allege any factual basis for the claim that the slogan was
false or misleading—the allegation that the product wasn’t actually made in the
USA was conclusory and devoid of supporting facts.  Alfasigma could amend to fix this problem, if
it could do so.
Then, the court found that the complaint failed to
sufficiently allege injury in fact by failing to allege anything more than that
Alfasigma had been harmed by the falsity. 
[Query: without Breckinridge in the picture, shouldn’t it have been
enough to allege the falsity and materiality of the claims? In that case it
would follow almost automatically that business gained by Nivagen would have
been lost by Alfasigma, unless you believe that a generic substitute is going
to grow the market somehow.]

from Blogger https://ift.tt/2pmWnr2

Posted in Uncategorized | Tagged | Leave a comment

only “laconic” resellers allowed: court refuses to dismiss complaint against reseller of Chanel goods

Chanel, Inc. v. WGACA, LLC, 2018 WL 4440507, No. 18 Civ.
2253 (LLS) (S.D.N.Y. Sept. 14, 2018)
Depressing but unsurprising: Chanel’s claims against used
goods-seller What Goes Around Comes Around proceed because WGACA may have been
too forward in telling the world that it could provide legitimate Chanel
products.  Chanel is appalled that WGACA
“uses the Chanel trademark and brand in its advertising and promotions,
although WGACA is not an authorized Chanel retailer or affiliated with Chanel.”  Its retail stores “prominently feature the
Chanel brand. Its store in East Hampton is decorated with a facsimile of a
giant Chanel No. 5 perfume bottle as a promotional advertisement, and the sign
in front of its SoHo store lists several brands, but lists ‘Vintage Chanel’ at
the top of the sign in larger print than the other brands, and its window
display items are all Chanel-branded.” WGACA’s website “offers more
Chanel-branded products for sale than those of any other brand,” features a
Chanel sale, and lists Chanel first under the non-alphabetical heading “Shop by
Brand.” WGACA’s social media includes quotations of Coco Chanel, photographs of
Chanel-branded products, and photographs of models and public-opinion influencers
wearing or carrying Chanel handbags, including photographs from previous Chanel
ads. They tag photos of Chanel-branded products with “#WGACACHANEL” and refer
to Chanel-branded products as “our #WGACACHANEL.”
WGACA’s website contains a section titled “Authenticity
Guaranteed,” which states, “Any piece purchased at What Goes Around Comes
Around or one of our retail partners has been carefully selected, inspected and
is guaranteed authentic.” WGACA also provides letters of authenticity to its
customers, e.g., “This letter confirms that item Q6HCHK00KB000 Chanel Black
Long Tissue Box is an authentic Chanel decoration.” But the guarantee comes
from WGACA; Chanel has not inspected or authenticated WGACA’s inventory.
Chanel plausibly stated a claim.  For example, #WGACACHANEL might create the
impression that WGACA is affiliated with Chanel or is an authorized Chanel
retailer. Also, WGACA’s extensive unauthorized use of the Chanel brand and
trademarks might constitute false advertising or endorsement, given the
extensive use of Chanel images and marks. Nominative fair use is no help
because this is the Second Circuit. “WGACA’s Chanel-branded items would be
readily identifiable as Chanel without the #WGACACHANEL hashtag and the
multiple uses of Chanel’s name and trademark in the hashtags,” and the special
prominence it gave to Chanel made it plausible that WGACA caused confusion by
using the mark too prominently or too often. And #WCAGACHANEL and WGACA’s
guarantees of authentication “of themselves” might suggest sponsorship or
endorsement by Chanel.
First sale also didn’t help because WGACA “did much more
than laconically resell Chanel-branded products: its presentations were
consistent with selling on Chanel’s behalf.” 
I didn’t realize that one had to be John Wayne to take advantage of
first sale (and there is probably a useful gender analysis to be done here;
fashion is excessive, but WGACA is apparently not allowed to be).
State common law unfair competition claims are nearly
identical but require bad faith; the court found that the complaint didn’t
plausibly allege bad faith intent to confuse. 
“If anything, the amended complaint shows that WGACA’s intent was to
display the Chanel brand conspicuously, and emphasize that their source was
Chanel.” Section 349 and 350 claims were, however, plausibly pled; they don’t
require bad faith, only deceptive/misleading conduct. 

from Blogger https://ift.tt/2MJ6eRj

Posted in Uncategorized | Tagged , | Leave a comment

Accurate statement that SPLC called a group a “hate group” isn’t plausibly misleading without more

Liberty Counsel, Inc. v. GuideStar USA, Inc., — Fed.Appx.
—-, 2018 WL 4339716 (Mem), No. 18-1157 (4th Cir. Sept. 11, 2018)
Who controls procedure controls substance.  The district court granted GuideStar’s motion
to dismiss Liberty’s Lanham Act false advertising claim against it.  GuideStar is a nonprofit organization that
maintains an online directory of profiles on other nonprofits, including
Liberty, an organization dedicated to advancing Christian causes. After the
Southern Poverty Law Center designated Liberty as a hate group, GuideStar added
a banner to Liberty’s profile revealing this designation.  Liberty sued and the district court
determined that there was no commercial speech.
The court of appeals affirmed on alternate grounds: failure
to properly allege misleadingness. Liberty conceded that the SPLC had in fact
designated it as a hate group. Liberty alleged that this designation was
misleading, but “a complaint must state facts demonstrating that the
defendant’s liability is plausible, not merely possible.” “Here, other than
identifying a broad swath of people whom the banner allegedly deceived, Liberty
baldly alleged customer confusion without providing ‘further factual
enhancement.’”  But what additional facts
would demonstrate misleadingness?  The
court doesn’t say, probably because to say would get require explaining what it
would take for “designated as hate group” to be false (since misleadingness
ultimately depends on consumers reaching false, that is falsifiable/verifiable
and untrue, conclusions from non-facially false statements).  How could the implication of this truthful
statement about the designation be anything other than opinion?  The court might be suggesting that it’s not
impossible that some story could be told about this, but it would require a lot
more in the way of detailed allegations. 
I have to say it’s a bit weird to me that the same court that refused to
recognize a claim in the GNC case is
less decisive about hate groups.

from Blogger https://ift.tt/2pqXPsu

Posted in Uncategorized | Tagged | Leave a comment

New verse, same as the first in Sony/Michael Jackson case

Serova v. Sony Music Entertainment, 2018 WL 4356891, — Cal.Rptr.3d
—-, No. B280526 (Ct. App. 2018)
The court amends its opinion finding that Sony’s advertising
that Michael Jackson was the performer of all the songs on the posthumous
Jackson album Sony released wasn’t commercial speech, but the amendment doesn’t make things any
better.  This provides an interesting
contrast to the other day’s One A Day opinion. 
The court here adds a footnote arguing that it didn’t matter whether
consumers would have understood Sony’s advertising to make factual claims about
the singer’s identity. What mattered instead was Sony’s lack of personal
involvement in creating the recordings [pretending that “Sony” is the kind of
entity that can have personal involvement]. It’s not that Sony’s statement is
opinion (in which case consumer understanding of what claim was being made
would be relevant), it’s that Sony’s lack of personal knowledge of its own
business operations makes the speech noncommercial.
Obviously, this creates pretty bad incentives for
corporations, but I think it’s worth reiterating that this is also inconsistent
with Kasky, on which the court of appeals purportedly relies, since Nike was
making statements about its subcontractors’ practices that the California
Supreme Court concluded were commercial speech. [Nike’s defenders even argued
that, precisely because it was talking about its subcontractors, the argument
that commercial speech has greater verifiability than other kinds of speech
shouldn’t apply.]  Nike’s statements were
the kinds of factual claims, including claims about Nike’s outsourcing
practices and their results, that it was in a better position to verify than
consumers. Consumers were also likely to rely on Nike’s expertise and greater
relative access to knowledge, as the Bayer court observed with respect to
Bayer.  To the extent that Nike may have
lacked “actual” knowledge, that was (1) a creation of Nike’s own choices to
subcontract rather than to do the work itself, for which it was responsible
(the analogy between that and the situation here is fairly strong), and (2) a reason that
Nike should have verified its statements rather than just saying them. [In the
actual situation involved in Nike, Nike maintained that it took steps to
substantiate its advertising claims—it simply took the position in the
California and US Supreme Courts that it didn’t have to do so and should be
able to win dismissal even assuming it had made those claims without knowing if
they were true.]

from Blogger https://ift.tt/2xgd5Mb

Posted in Uncategorized | Tagged , , , | Leave a comment

New verse, same as the first in Sony/Michael Jackson case

Serova v. Sony Music Entertainment, 2018 WL 4356891, — Cal.Rptr.3d
—-, No. B280526 (Ct. App. 2018)
The court amends its opinion finding that Sony’s advertising
that Michael Jackson was the performer of all the songs on the posthumous
Jackson album Sony released wasn’t commercial speech, but the amendment doesn’t make things any
better.  This provides an interesting
contrast to the other day’s One A Day opinion. 
The court here adds a footnote arguing that it didn’t matter whether
consumers would have understood Sony’s advertising to make factual claims about
the singer’s identity. What mattered instead was Sony’s lack of personal
involvement in creating the recordings [pretending that “Sony” is the kind of
entity that can have personal involvement]. It’s not that Sony’s statement is
opinion (in which case consumer understanding of what claim was being made
would be relevant), it’s that Sony’s lack of personal knowledge of its own
business operations makes the speech noncommercial.
Obviously, this creates pretty bad incentives for
corporations, but I think it’s worth reiterating that this is also inconsistent
with Kasky, on which the court of appeals purportedly relies, since Nike was
making statements about its subcontractors’ practices that the California
Supreme Court concluded were commercial speech. [Nike’s defenders even argued
that, precisely because it was talking about its subcontractors, the argument
that commercial speech has greater verifiability than other kinds of speech
shouldn’t apply.]  Nike’s statements were
the kinds of factual claims, including claims about Nike’s outsourcing
practices and their results, that it was in a better position to verify than
consumers. Consumers were also likely to rely on Nike’s expertise and greater
relative access to knowledge, as the Bayer court observed with respect to
Bayer.  To the extent that Nike may have
lacked “actual” knowledge, that was (1) a creation of Nike’s own choices to
subcontract rather than to do the work itself, for which it was responsible
(the analogy between that and the situation here is fairly strong), and (2) a reason that
Nike should have verified its statements rather than just saying them. [In the
actual situation involved in Nike, Nike maintained that it took steps to
substantiate its advertising claims—it simply took the position in the
California and US Supreme Courts that it didn’t have to do so and should be
able to win dismissal even assuming it had made those claims without knowing if
they were true.]

from Blogger https://ift.tt/2xgd5Mb

Posted in Uncategorized | Tagged , , , | Leave a comment

2 week difference leads to $10 million in damages in pregnancy estimator case

Church & Dwight Co. v. SPD Swiss Precision Diagnostics
GmbH, No. 14-CV-585 (AJN), 2018 WL 4253181 (S.D.N.Y. Sept. 5, 2018)
Church & Dwight won an injunction, affirmed by the Second
Circuit, against SPD’s advertising of its “Clearblue Advanced Pregnancy Test
with Weeks Estimator,” and the court here awarded nearly $1 million in damages,
but not fees, SPD’s profits, or treble damages/punitive damages under state law.
While “causation must first be established,” a court may
engage in “some degree of speculation” in determining the amount of damages.
“[T]he district court may take into account the difficulty of proving an exact
amount of damages from false advertising, as well as the maxim that ‘the
wrongdoer shall bear the risk of the uncertainty which his own wrong has
created.’ ”  Thus, the plaintiff’s burden
is to show
 “that its damages
calculation is a ‘fair and reasonable approximation’ of its lost profits.”
“C&D’s leading home pregnancy test brand, First
Response, has been the market leader for many years, and SPD’s leading brand,
Clearblue, has been First Response’s primary competitor.” C&D’s damages
expert used all of SPD’s sales of the accused product to estimate damages, then
calculated lost profits by using C&D’s market share to estimate how many of
SPD’s sales would have gone to C&D had the Weeks Estimator not been sold,
and multiplying that by C&D’s per-test stick incremental profit margin, resulting
in an estimate of $9,955,018.
SPD’s expert agreed that market share allocation was an
appropriate approach, but calculated lost profits of only [redacted, which is
annoying but not dispositive because his calculation was ultimately
rejected].  The “large” difference
between the two calculations came from SPD’s expert’s use of the consumer
reaction survey as a proxy for loss causation and his use of a lower per-stick
profit margin.
C&D’s expert assumed that all of the sales of the Weeks
Estimator were connected to the false advertising of the product’s key
differentiating feature, despite his admission that he cannot be sure that
every person who bought the Weeks Estimator bought it because of the
advertising or because they were deceived by the advertising.  C&D argued that this assumption was
warranted because: (1) Every consumer who bought the Weeks Estimator was
exposed to at least part of SPD’s marketing campaign, and weeks estimation was
both SPD’s key message and the key feature differentiating the product, which
was more expensive than C&D’s competing Clearblue product.  (2) Retailers’ decisions about whether to
stock the Weeks Estimator, how much shelf space to give it, and where to place it
on store shelves likely were influenced by false advertising, affecting
purchasers.  C&D’s expert assumed
that, but for that false advertising, the launch of the Weeks Estimator SKU “would
not have had an incremental effect on [SPD’s] First Response stick sales.”
The court found C&D’s expert’s assumptions to be
reasonable: “this is a competitive market in which the parties own the top two
brands; and there is one key distinguishing feature between the Product and
similar test sticks—a feature that was the subject of false advertising
directed at both consumers and retailers.” Also, evidence suggesting that some
subset of consumers were unaffected by the advertising wasn’t persuasive.
SPD offered a survey in which prospective pregnancy test
buyers were asked about their willingness to purchase two product concepts,
which found that 81% of respondents would “definitely purchase” the product
estimating pregnancy from the last menstrual period, and 84% of respondents
would “definitely purchase” the product that estimates pregnancy from
ovulation, which they understood to be different from a doctor’s estimate. Thus,
SPD argued, the key differentiating feature—the test’s ability to estimate the
number of weeks since ovulation—would still induce purchases even in the
absence of false advertising. But that survey used statements describing how
pregnancy duration was measured, not how that duration was expressed, which was
the key problem with Weeks Estimator. Also, the survey offered only two
extremes—would definitely purchase, and would not purchase—and showed each
participant only one product description, unlike the real world offering
options for comparison.  It isn’t
surprising that both descriptions were popular, compared to nothing else.
SPD also argued that international versions of the same
product were successful absent the false advertising, and that C&D understood
even without looking at the ads that the Weeks Estimator would take business
from it regardless of the false advertising. 
As for the different international marketing, “the absence of a formal
finding of falsity by a court does not necessarily mean that the international
advertising was not false or misleading.” While some international versions had
more descriptive names—principally, “Clearblue Digital Pregnancy Test with
Conception Indicator”—and/or contained a chart on the packaging that compared
the product’s measure of weeks since ovulation to a doctor’s estimate, other
foreign ads touted the product as being “As Accurate as a Doctor’s Test” and
featured language and imagery similar to those found misleading in the US.  As for the impact of the innovative nature of
the product itself, C&D argued that its documents and internal discussions
reflected its fear of the commercial strength of the product with attendant
misleading advertising. The court agreed.
Finally, SPD tried to use C&D’s survey, conducted by Hal
Poret, which C&D used to show an actionable level of consumer confusion, as
a measurement of how many sales were attributable to the at-issue advertising
or at least as evidence that not all sales of the product were attributable to
false advertising. But given that every purchaser and retailer was exposed to
intentionally misleading advertising about the key differentiating feature of
the product, and that the evidence about other reasons for purchase was
speculative, considering all the sales was not just reasonable, it was the most reasonable assumption.
The Poret survey wasn’t intended as a proxy for tying the
false advertising to the lost profits. It found roughly 20% net deception,
defining deception as answering both that the product estimates the number of
weeks a woman is pregnant and that the product’s estimate is the same as a
doctor’s estimate of weeks pregnant.  Poret had never taken the position that the
results of a study like this could be used to predict the percentage of actual
purchasers who were deceived.  He
contended that you can’t treat prospective purchasers as if they were actual
purchasers; it is even possible, though unlikely, that 100% of the actual
purchasers could have fallen within the subset of prospective purchasers who
were misled. He further testified that his survey didn’t account for the impact
of non-package advertising, and that survey likely understates the degree of
deception among respondents. For example, the control package he used still
identified the product as the “Clearblue Advanced Pregnancy Test with Weeks
Estimator,” which might have led some in the control group to make the same
mistake as confused people in the test cell. 
It is possible to use survey results as a proxy for damages causation,
but C&D’s market share was a better proxy in this litigation.
SPD also argued that the Weeks Estimator disproportionately
cannibalized Clearblue products rather than harming C&D’s products in
proportion to its market share.  C&D
offered a regression analysis reaching the opposite conclusion. SPD’s
criticisms were “atmospherically compelling in that they lay bare some of the
difficulties in finding a way to calculate the effect of the unlawful
activity—SPD’s false advertising—while controlling for all other forces
affecting market share.” But these criticisms were undermined by its own expert’s
reliance on a market share allocation methodology, which “inherently accounts
for a range of market factors.”  In any
event, C&D’s expert’s conclusions, backed by his regression, were
reasonable.
“While it is likely that some consumers bought the Weeks
Estimators for reasons disconnected from the false advertising, SPD has not
supported any one of these alternative reasons, or even the totality of these
other reasons, with evidence sufficient to overcome the evidence of the
reasonableness of [C&D]’s core market share assumption. SPD pervasively
falsely advertised the Product from its launch, never advertised it in a
truthful manner, and has not affirmatively offered any of its own data
regarding the number of purchasers who were not deceived ….” Most crucially,
the false advertising was about the key feature differentiating the Weeks
Estimator from other products, making this methodology and core assumptions that
much more reasonable.
The court denied disgorgement in addition to lost profits, because
that would be overcompensatory. Nor did the court treble the award under the
Lanham Act, even assuming that the false advertising was willful (at the
liability stage the court found that SPD knew that consumers would misunderstand
the weeks estimation claim).  “Whatever
the ‘intangible’ harm caused by SPD’s false advertising, the Court finds that
its award of nearly $10 million is both adequate compensation to C&D for
all harm done and adequate deterrence against any future false advertising by
SPD.” Punitive damages under N.Y. Gen. Bus. Law § 349 likewise require “clear,
unequivocal and convincing evidence that [the defendant’s] conduct was gross,
involved high moral culpability, and was aimed at the general public,” and SPD’s
conduct wasn’t sufficiently egregious. Nor was this an exceptional case for fee
purposes. SPD’s litigation positions were reasonable and the court previously
rejected C&D’s attempt to get sanctions for disobeying the injunction.

from Blogger https://ift.tt/2p3eFO1

Posted in Uncategorized | Tagged , | Leave a comment

In plagiarism/false attribution case, use was de minimis, fair, and protected by 1A

Israel v. Strassberg, 2018 WL 4290394, No. 2:15-CV-741 (D.
Utah. Sept. 7, 2018)
Israel entered the Ph.D. Psychology program at the
University of Utah, which required a master’s thesis, and Strassberg was her advisor.
Israel’s master’s thesis turned on the concept of relying on viewing time to
measure a subject’s sexual interest. To carry out a study for her thesis,
Israel selected and arranged a set of images, wrote instructions and survey
questions, and created the syntax necessary for the study to be administered by
a computer program.  Strassberg felt that
her work was important to the field of study and, after the thesis was approved,
Strassberg submitted it for publication in an academic journal with his name
included as second author. Their relationship eventually became strained.
Strassberg was also defendant Rullo’s advisor, and he
allegedly shared Israel’s work with Rullo without authorization.  Rullo’s subsequent master’s thesis used
Israel’s study materials and methods, building on it by examining gay and
lesbian populations where Israel had only looked at heterosexuals.  Strassberg likewise submitted this thesis for
publication, where it included Strassberg as second author and Israel as third
author, allegedly without her consent.
Israel “left the University on contentious terms without
completing her Ph.D. program.” But Strassberg’s graduate students continued to
build on her original research.
Copyright infringement: Israel registered: (1) the
arrangement and compilation of the images used in the viewing time study; (2)
the written instructions and surveys included in the viewing time study; and
(3) the computer syntax, which allowed her to administer the study via
computer. Baker v. Selden instructs: “[W]hilst
no one has a right to print or publish his book, or any material part thereof,
as a book intended to convey instruction in the art, any person may practice
and use the art itself which he has described and illustrated therein.”  This was Baker
redux. Israel’s ideas—“the use of images of attractive individuals and scenery,
tracking viewing time as a measure of sexual interest, asking participants to
rate images on a scale, inquiring as to participants’ sexual orientation and/or
sexual interests and comfort levels, and other elements related to the process
and method of the study”—were free for all to use.
What about Israel’s specific expression of the ideas?  Rullo’s thesis allegedly copied the “substance”
of Israel’s literature review; explained the same stimulus and procedure as
Israel did; used her data; copied her methods; and recited her original ideas,
all while citing her numerous times.  None
of this constituted infringement of protectable elements.  There was direct copying of three sentences
from the registered works:
We would like you to rate each of
the following pictures in terms of how sexually appealing you find the picture
to be. Please make your ratings on a scale of 1-7 where 1 is “not at all
sexually appealing” and 7 is “extremely sexually appealing.” We are interested
in your rating of each picture, not how you believe others might rate the
picture.
This copying was not significant enough to qualify as infringement,
and even if it had been, it would be fair use. 
[Yay!  Separate analysis of the
two reasons!]  Fair use: (1) nonprofit
educational purpose; (2) the original was highly factual, not highly expressive;
(3) only a minimal amount was copied word for word and the qualitative
significance was low because the copying “merely explains a process used in
conducting the study”; and (4) unrestricted copying of the type Rullo engaged
in would not have a substantially adverse impact on the potential market for
the original.  Rather, “[a]cademic
studies and publications often flow from previous studies and publications.
Overlap and building upon research materials is critical to the advancement of
science.”  Even if Israel had registered
more of her work and could thereby claim more copying as infringement, that
copying too would be insufficient to infringe and also fair.
The same rationales also protected the published articles and
Rullo’s dissertation; specifically, the dissertation simply said that “the
stimuli and procedures in the present study were identical to those used with
the heterosexual” and cited Israel.  “A
description of the copyrighted materials” couldn’t create a factual issue on
substantial similarity, nor could use of Israel’s materials in conducting the
studies underlying the findings contained in other documents/publications.
Lanham Act: Israel argued that defendants falsely attributed
authorship to her in presentations and papers and failed to appropriately
attribute her authorship in [possibly other?] presentations and publications. Rather
than pointing to Dastar, the court
ruled that her name wasn’t used “in commerce” because the articles and presentations
at issue weren’t “commercial” but rather scientific and educational. “Academic
publications fall outside of the purview of congressional reach under the
commerce clause because they include non-commercial speech, which is entitled
to the highest levels of protection by the First Amendment.”  Even if the publications had paying subscribers,
that didn’t make individual articles into commercial speech subject to the
Lanham Act.  Plus, her name wasn’t
used/misused “in commerce” because including or excluding her name didn’t
provide any commercial benefit to defendants or to the publications.  [This is really “use as a mark,” but ok.]  Israel also provided no evidence that she
suffered a loss as a result.  Summary
judgment granted.
There was a state law false advertising claim, over which
the court declined to exercise its supplemental jurisdiction, though given the
First Amendment rationale of the Lanham Act result I might’ve gone a different
direction with that.

from Blogger https://ift.tt/2NbBUUi

Posted in Uncategorized | Tagged , , , , , , | Leave a comment